Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection.
We compared the efficacies of quinupristin-dalfopristin (Q-D; 30 mg/kg of body weight every 8 h) and vancomycin (60 mg/kg twice daily), alone or in combination with rifampin (10 mg/kg twice daily), in a rabbit model of methicillin-resistant Staphylococcus aureus knee prosthesis infection. In contrast to vancomycin, Q-D significantly reduced the mean log(10) CFU per gram of bone versus that for the controls. The combination of rifampin with either Q-D or vancomycin was significantly more effective than monotherapy.
Saleh-Mghir
Azzam
A
INSERM EMI-U 9933, Hôpital Bichat-Claude Bernard, Paris, France.
Ameur
Nourdine
N
Muller-Serieys
Claudette
C
Ismael
Farid
F
Lemaitre
Françoise
F
Massias
Laurent
L
Feger
Céline
C
Bléton
Rémy
R
Crémieux
Anne-Claude
AC
D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D000904:Antibiotics, Antitubercular / Q000008:administration & dosage*; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007595:Joint Prosthesis; D016106:Methicillin Resistance; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology; D011817:Rabbits; D012293:Rifampin / Q000008:administration & dosage*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D014018:Tissue Distribution; D014640:Vancomycin / Q000493:pharmacokinetics / Q000627:therapeutic use; D014769:Virginiamycin / Q000008:administration & dosage* / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D014769:Virginiamycin; C113825:quinupristin; D014640:Vancomycin; D012293:Rifampin